Last reviewed · How we verify
TC chemotherapy
TC chemotherapy is a Chemotherapy combination regimen Small molecule drug developed by Agendia. It is currently FDA-approved for Breast cancer (adjuvant and neoadjuvant treatment), Non-small cell lung cancer.
TC chemotherapy is a combination regimen of docetaxel (Taxotere) and cyclophosphamide that disrupts microtubule dynamics and cross-links DNA to kill rapidly dividing cancer cells.
TC chemotherapy, which consists of a combination of drugs including Docetaxel and Cyclophosphamide, is used to treat various conditions such as breast cancer, HER 2 Negative Breast Cancer, and Acute Myeloid Leukemia. TC chemotherapy is a small molecule modality, classified as a type of chemotherapy treatment.
At a glance
| Generic name | TC chemotherapy |
|---|---|
| Sponsor | Agendia |
| Drug class | Chemotherapy combination regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Docetaxel is a taxane that stabilizes microtubules and prevents their disassembly, leading to cell cycle arrest and apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing replication and transcription. Together, TC exploits complementary mechanisms to enhance cytotoxic effects against cancer cells.
Approved indications
- Breast cancer (adjuvant and neoadjuvant treatment)
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Alopecia
- Peripheral neuropathy
- Fatigue
- Mucositis
Key clinical trials
- A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
- A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer (PHASE1)
- Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI (PHASE1)
- Tc99m Sestamibi Molecular Breast Imaging (NA)
- CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon） (PHASE3)
- Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer (PHASE2)
- ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer (PHASE2)
- TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TC chemotherapy CI brief — competitive landscape report
- TC chemotherapy updates RSS · CI watch RSS
- Agendia portfolio CI
Frequently asked questions about TC chemotherapy
What is TC chemotherapy?
How does TC chemotherapy work?
What is TC chemotherapy used for?
Who makes TC chemotherapy?
What drug class is TC chemotherapy in?
What development phase is TC chemotherapy in?
What are the side effects of TC chemotherapy?
Related
- Drug class: All Chemotherapy combination regimen drugs
- Manufacturer: Agendia — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Breast cancer (adjuvant and neoadjuvant treatment)
- Indication: Drugs for Non-small cell lung cancer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing